| November 24, 2016 | Scientists and researchers from around the world gathered this week in Israel for the inauguration of the Technion Integrated Cancer Center (TICC), a first-of-its kind hub for global cancer research, which will expedite the discovery of new diagnostic tools and treatments through a collaborative “bench-to-bedside”approach. In addition to serving as a hub for multiple fields of research, the TICC will also be a nexus for the Technion’s five affiliated hospitals that run clinical trials. It will be co-led by Professor Ze’ev Ronai and Distinguished Professor Aaron Ciechanover – who along with Technion Professor Avram Hershko and the late Dr. Irwin Rose won the 2004 Nobel Prize for the discovery of the ubiquitin system, a discovery which led to the development of efficient anti-cancer drugs, e.g. Velcade® for Multiple Myeloma.
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors

Ashdod Port Investing In Startups As Part Of Innovation Strategy

Facebook comments